ClinicalTrials.gg
CompletedNCT05643404Updated Aug 21, 2024

Effects of Isolated LBBB on Maximal Functional Capacity

An observational study in Left Bundle-Branch Block, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Completed at 1 site in Spain. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
162
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Left bundle branch block (LBBB) has been commonly associated with adverse cardiovascular (CV) events, but the effect of an isolated LBBB on maximal functional capacity is not well characterized.

The study's main objective is to evaluate the effect of LBBB on maximum functional capacity.

Read the detailed description

Left bundle branch block (LBBB) has been commonly associated with adverse cardiovascular (CV) events, but the effect of an isolated LBBB on maximal functional capacity is not well characterized.

The main objective of the study is to evaluate the effect of LBBB on maximum functional capacity (objectively evaluated by the maximum oxygen consumption -VO2max- at peak exercise in a cardiopulmonary stress test -CPET-) in subjects with LBBB without known cardiovascular disease and compare these data with controls without LBBB.

This is a prospective study that will be carried out in a single centre. All patients with a diagnosis of LBBB and without evidence of structural heart disease in imaging tests will be enrolled. For each candidate with LBBB, one control without LBBB and matched for age, sex, body surface area, and daily physical activity will be selected. All included subjects will undergo a CPET and echocardiography. A sample size estimation [alpha: 0.05, power: 80%, and a clinically significant VO2max difference between groups of at least 10%] of 148 subjects (74 subjects with LBBB + 74 controls) would be necessary to test our hypothesis.

02

Conditions studied

  • Left Bundle-Branch Block

Browse trials for

Keywords

  • Functional capacity
  • Cardiac dyssynchrony
  • Myocardial deformation
03

In context

Bundle-Branch Block

94 studies on the registry are indexed under Bundle-Branch Block; 30 are open to participants now.

This study's enrollment of 162 is close to the median of 162 across 33 observational studies indexed under Bundle-Branch Block.

Browse Bundle-Branch Block studies →

Lead sponsor

Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

A total of 74 consecutive adults with a previous diagnosis of isolated left bundle branch block recruited from general practitioner outpatient clinics will be included.

For each candidate with an isolated left bundle branch block, one control without a left bundle branch block and matched for age, sex, body surface area, and daily physical activity will be selected from general practitioner outpatient clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult >18 years old
  • criteria of left bundle branch block (for controls without left bundle branch block )
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Inability to perform a maximal baseline exercise test;
  • Structural heart disease, valve heart disease or diastolic dysfunction estimated by two-dimensional echocardiography;
  • Previous ischemic heart disease, heart failure, myocardiopathy or myocarditis
  • Effort angina during cardiopulmonary exercise testing (CPET);
  • Any moderate pulmonary disease;
  • Anaemia
  • \< 55%.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
162 participants (actual)
Patient registry
No

Groups and cohorts

  • Isolated LBBB

    Subjects with left bundle branch block in the absence of clinically detectable heart disease

    Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Echocardioghaphy

  • Matched controls without LBBB

    Subjects without left bundle branch block and in the absence of clinically detectable heart disease

    Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Echocardioghaphy

Interventions

  • Diagnostic testCardiopulmonary exercise testing

    Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.

  • Diagnostic testEchocardioghaphy

    Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography

06

What researchers measure

Primary outcomes

  1. Peak oxygen consumption

    Peak oxygen consumption at peak exercise of a maximal symptom-limited cardiopulmonary exercise testing. Units peak oxygen consumption : mL/kg/min

    Time frame: Eligible patients will perform only one cardiopulmonary exercise testing on the first visit. Peak oxygen consumption will be evaluated during the procedure and compared to control patients.

Secondary outcomes

  1. Left ventricular end-diastolic volume

    Evaluate left ventricular end-diastolic indexed volume by echocardiography at rest. Unit: ml/m2

    Time frame: Eligible patients will perform only one echocardiography on the first visit. Left ventricular end-diastolic volume will be assessed during the procedure and compared to control patients.

  2. Left ventricular ejection fraction

    Evaluate left ventricular ejection fraction by echocardiography at rest. Unit: %

    Time frame: Eligible patients will perform only one echocardiography on the first visit. Left ventricular ejection fraction will be assessed during the procedure and compared to control patients.

07

Study locations

1 site
  • Marta Peiro
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: Undecided — Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 8, 2022
StartActual
Dec 22, 2022
Primary completionActual
Jul 9, 2024
CompletionActual
Jul 9, 2024
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05643404
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Dec 22, 2022
Primary completion
Jul 9, 2024
Completion
Jul 9, 2024
Last update
Aug 21, 2024

Study contacts

Patricia Palau, MD, PhD
principal investigator · INCLIVA

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion